Pharmacy News and Research

RSS

Community pharmacy, also known as retail pharmacy, is the most common type of pharmacy that allows the public access to their medications and advice about their health. Traditionally known as a chemist, it is the healthcare facility that is responsible for the provision of pharmaceutical service to a specific community group or region.

Five UK research hubs to develop technologies for healthier lives

Five new research and partnership hubs are being backed by over £52 million from the UK government through UK Research and Innovation (UKRI), to develop tools that help people stay healthier for longer.

6 Nov 2026

Review examines translational bottlenecks for plant-derived anti-inflammatory compounds

A review led by Professor Weidong Zhang at the School of Pharmacy, Naval Medical University, was published in Volume 2 of the journal Immunity & Inflammation on October 27, 2026. The article systematically examines the translational bottlenecks and potential solutions for plant-derived anti-inflammatory compounds.

5 Nov 2026

Compound YZG-331 leverages gut microbiota to improve sleep in mouse models of insomnia

This new article publication from Acta Pharmaceutica Sinica B discusses how interactions between the investigational compound YZG-331 and the gut microbiota contribute to its sleep-promoting effects in mouse models of insomnia.

5 Nov 2026

Anti-PEG antibodies drive contrasting liposome skin toxicity across species

This new article publication from Acta Pharmaceutica Sinica B discusses how anti-polyethylene glycol antibodies affect the movement of stealth liposomes from blood into skin, revealing contrasting distribution and toxicity patterns in mice and rats.

5 Nov 2026

Pattern-based patient selection associated with positive clinical trial results

This new article publication from Acta Pharmaceutica Sinica B discusses the association between using traditional Chinese medicine patterns to select participants and statistically significant primary outcomes in randomized placebo-controlled trials of Chinese herbal formulas.

5 Nov 2026

New covalent inhibitor targets DNAJC9 to reduce sepsis inflammation

This new article publication from Acta Pharmaceutica Sinica B discusses the discovery of the covalent inhibitor A12 and the identification of DNAJC9 as a potential drug target for sepsis-associated inflammation.

5 Nov 2026

Targeted nanoimmunotherapy reduces atherosclerotic plaque burden in mice

This new article publication from Acta Pharmaceutica Sinica B discusses a targeted nanoimmunotherapy designed to restore macrophage clearance of dying cells, promote an anti-inflammatory phenotype, and reduce atherosclerotic plaque burden in mice.

4 Nov 2026

Genetic variant tied to liver injury from blood pressure drugs

This new article publication from Acta Pharmaceutica Sinica B discusses the clinical features and genetic associations of rare liver injury caused by antihypertensive medications.

4 Nov 2026

Synthetic DNA molecules enable precise targeting of cancer-linked genes

Researchers have developed a promising new approach that uses synthetic DNA molecules to target cancer-linked genes directly, opening new possibilities for future treatments, diagnostics and biological research.

3 Nov 2026

Natural body gas could help treat severe skin and wound infections

A gas naturally produced by our own bodies could one day help treat skin and wound infections, potentially offering a new approach alongside conventional antibiotics.

3 Nov 2026

New study links cannabis use to increased cardiovascular risk

Cannabis use, including marijuana, appears to be linked with increased cardiovascular risk, especially for stroke, making it an important consideration for heart disease and stroke prevention and counseling, according to independent, new preliminary research to be presented at the American Heart Association's Scientific Sessions 2026.

2 Nov 2026

Novel transporter protein discovery opens new pathways for central nervous system therapies

Researchers at the University of Eastern Finland have identified a transporter protein with the potential to open new avenues for improving creatine delivery into the brain and for developing other therapies targeting the central nervous system.

29 Oct 2026

Millions get GLP-1 drugs through channels insurance records may miss

Researchers analyzed reports from 9,150 US adults and found that current or previous GLP-1/GIP use rose from 8.2% to 12% between March 2024 and October 2025, largely driven by weight-loss indications. They also estimated that approximately one-third of users obtained treatment through nontraditional channels that standard insurance claims may fail to capture.

26 Oct 2026

Marine-derived compound shows promise against deadly brain eating amoeba

Primary amoebic meningoencephalitis (PAM), a parasitic disease that causes the rapid deterioration of brain tissue, is one of the most lethal infections known, with a fatality rate exceeding 97%.

26 Oct 2026

Fish consumption may help reduce hypertensive disorders of pregnancy

A new prospective study from Japan explored whether fish consumption before and during pregnancy is linked to hypertensive disorders of pregnancy, including gestational hypertension and preeclampsia.

23 Oct 2026

Study identifies potential new ways to treat the most common type of bowel cancer

Major new research published today identifies potential new ways to treat the most common type of bowel cancer in Ireland.

23 Oct 2026

$8.2 million grant advances on-demand male contraceptive development

Weill Cornell Medicine has received a four-year, $8.2 million grant from the National Institute of Child Health and Human Development (NICHD) to develop and test an experimental on-demand male contraceptive pill that temporarily stops sperm in their tracks

22 Oct 2026

Study challenges concerns linking ADHD medication to self-harm risk

The risk of self-harm amongst people with attention deficit hyperactivity disorder (ADHD) is highest before people start ADHD medication, rather than after treatment begins, according to new research led by Aston University.

22 Oct 2026

Clinical trial establishes effective HIV dosing regimen for full-term newborns

An international study conducted through the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network including researchers at the University of California San Diego helped inform the U.S. Food and Drug Administration's (FDA) recent approval of dolutegravir, a second-generation integrase inhibitor, for the treatment of human immunodeficiency virus (HIV-1) in newborns from birth.

22 Oct 2026